Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01505608 · ClinicalTrials.gov registry record · Phase 1
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma
A Phase 1 study, sponsored by Giselle Sholler.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01505608 is a Phase 1 study that was terminated before completion, run by Giselle Sholler. The registered enrollment target is 14 participants.
The verdict
NCT01505608, a Phase 1 study, was terminated before completion, sponsored by Giselle Sholler.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate a new investigational drug (TPI 287) for early relapsed neuroblastoma. An investigational drug is one that has not yet been approved by the Food and Drug Administration. This investigational drug is called TPI 287. This study will look at the tumor's response to the study drug, TPI 287, in combination with Irinotecan and Temozolomide versus the combination of Irinotecan and Temozolomide alone. This study will also evaluate the safety and tolerability of the study drug, TPI 287.
Interventions
- DRUG Temozolomide
- DRUG Irinotecan
- DRUG TPI 287
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-12 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01505608
The ClinicalTrials.gov registry entry for NCT01505608 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Giselle Sholler, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Temozolomide is the first listed.
NCT01505608 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01505608 about?
NCT01505608 is a clinical study titled "Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma". The purpose of this research study is to evaluate a new investigational drug (TPI 287) for early relapsed neuroblastoma. An investigational drug is one that has not yet been approved by the Food and Drug Administration. This investigational drug is called TPI 287. This study will look at the tumor's...
What is the current status of trial NCT01505608?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2011-12. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01505608?
The interventions under investigation include: Temozolomide (DRUG), Irinotecan (DRUG), TPI 287 (DRUG).
Who is sponsoring clinical trial NCT01505608?
This trial is sponsored by Giselle Sholler, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.